Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| EA8191 | ECOG-ACRIN | Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA8192 | ECOG-ACRIN | A Phase II/III trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA8211 | ECOG-ACRIN | Phase III Randomized Trial of Stereotactic Ablative Radiotherapy (SAbR) for Oligometastatic Advanced Renal Carcinoma (SOAR) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA8212 | ECOG-ACRIN | A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9131 | ECOG-ACRIN | A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) | Cancer Prevention and Control CIRB | Available to Open | |
| EA9152 | ECOG-ACRIN | A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9161 | Alliance | A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9171 | Alliance | BLAST MRD CML 1 Trial: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- A Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with CML and Persistently Detectable MRD | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9181 | ECOG-ACRIN | A Phase III Randomized Trial of Steroids +Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-positive Acute Lymphoblastic Leukemia in Adults | Adult CIRB - Late Phase Emphasis | Available to Open | |
| EA9213 | ECOG-ACRIN | A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia (T-ALL) | Adult CIRB - Late Phase Emphasis | Available to Open |